---
id: gero-trajectory-mapping
slug: gero-trajectory-mapping
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-12-23
researcher: AI Assistant
version: 4.1
name: Gero Trajectory Mapping - Aging Theory Synthesis
description: AI platform that synthesizes fragmented aging theories into unified model using Large Language Models (LLMs). Analyzes 100M+ longitudinal medical records to identify causal pathways underlying aging and disease. Separates irreversible aging processes from reversible diseases using thermodynamics and dynamic systems principles.
mission: To synthesize fragmented theories of aging and develop unified understanding of aging mechanisms using artificial intelligence, physics-informed models, and analysis of massive longitudinal medical datasets. Gero aims to identify causal pathways underlying aging and disease, separate irreversible aging processes from reversible diseases, and enable rational intervention design based on unified aging theory.
entity_data:
  focus: Application of physics and machine learning to aging research. Development of AI platforms for aging theory synthesis, trajectory mapping, and causal pathway discovery using large language models and physics-informed models.
  website: "https://gero.ai"
  industry: Biotechnology
  employees:
  note: Employee count not publicly disclosed. Company appears to be a small to medium-sized biotech startup.
  as_of: 2025
  legal_name: Gero Pte. Ltd.
  founded_note: Exact founding year not publicly disclosed. Company appears to have been active since at least 2015-2017 based on research activities.
taxonomy:
  geography: Singapore
  ai_approach: []
  ai_technology:
  - LLMs
  primary_focus:
  - Aging Clocks
  aging_approach:
  - Target Discovery
  - Diagnostics/Age Assessment
  target_biology:
  - Fibrosis
  - General Aging/Longevity
  ai_architecture:
  - LLMs
  ai_specialization: []
  development_stage: published
  organization_type: research
  organization_subtype: collaboration
  therapeutic_modality: []
organizations:
  -
    name: Gero
    role: primary
    org_type: company
    legal_name: Gero Pte. Ltd.
    founded: 2015
    website: "https://gero.ai"
    status: operational
    role_description: Primary organization - developer of the aging theory synthesis platform
  -
    name: Chugai Pharmaceutical
    role: partner
    org_type: company
    status: operational
    role_description: Joint research and license agreement partner for novel therapies
  -
    name: Pfizer
    role: partner
    org_type: company
    status: operational
    role_description: Research collaboration partner for target discovery in fibrotic diseases
products:
  -
    name: Aging Theory Synthesis Platform
    type: platform
    status: operational
links:
  -
    url: "https://gero.ai/about"
    type: website
    title: Gero AI - About
  -
    url: "https://www.pfizer.com/news/press-release/press-release-detail/longevity-biotech-gero-entered-research-collaboration"
    type: press_release
    title: Gero Enters Research Collaboration with Pfizer
  -
    url: "https://www.nature.com/articles/s41514-025-00277-2"
    type: research_publication
    title: Dissipative theory of aging based on dynamic systems analysis
  -
    url: "https://www.nature.com/articles/s43587-024-00631-1"
    type: research_publication
    title: Aging map revealing cell-specific effects of longevity strategies
  -
    url: "https://en.wikipedia.org/wiki/Peter_Fedichev"
    type: reference
    title: Peter Fedichev - Wikipedia
  -
    url: "https://www.gero.ai/hacking-aging"
    type: website
    title: Gero AI - Hacking Aging
  -
    url: "https://www.gero.ai/news/chugai-and-gero-enter-into-joint-research-and-license-agreement-to-develop-novel-therapies-for-age-related-diseases"
    type: press_release
    title: Gero and Chugai Enter into Joint Research and License Agreement
---

# Gero Trajectory Mapping - Aging Theory Synthesis

## Description

AI platform that synthesizes fragmented aging theories into unified model using Large Language Models (LLMs). Analyzes 100M+ longitudinal medical records to identify causal pathways underlying aging and disease. Separates irreversible aging processes from reversible diseases using thermodynamics and dynamic systems principles.

## Mission

To synthesize fragmented theories of aging and develop unified understanding of aging mechanisms using artificial intelligence, physics-informed models, and analysis of massive longitudinal medical datasets. Gero aims to identify causal pathways underlying aging and disease, separate irreversible aging processes from reversible diseases, and enable rational intervention design based on unified aging theory.

## Company Information

**Legal Name**: Gero Pte. Ltd.
**Industry**: Biotechnology
**Employees**: {"note":"Employee count not publicly disclosed. Company appears to be a small to medium-sized biotech startup.","as_of":"2025"}
**Focus**: Application of physics and machine learning to aging research. Development of AI platforms for aging theory synthesis, trajectory mapping, and causal pathway discovery using large language models and physics-informed models.
**Website**: https://gero.ai

## Scientific Background

```yaml
llm_synthesis: Large Language Models are used to synthesize fragmented aging theories by integrating diverse datasets. This approach expands the search space for intervention targets and enables systematic integration of aging theories that would be difficult to achieve manually.
dissipative_aging: "The dissipative theory of aging views aging as a dissipative process in biological systems, similar to dynamic systems where dissipation occurs due to non-conservative forces. This theoretical framework informs the platform's approach to modeling aging trajectories."
trajectory_mapping: The platform models individual aging trajectories using 100M+ longitudinal medical records. This allows identification of causal relationships underlying aging and disease, rather than just correlations. Physics-informed models help separate irreversible aging processes from reversible diseases.
entropy_and_resilience: Aging is associated with loss of systemic resilience due to increasing entropy. This physical framework allows the platform to distinguish between irreversible aging processes and reversible diseases, enabling targeted interventions to restore systemic resistance.
biological_justification: Aging involves multiple interconnected mechanisms (telomeres, oxidative stress, mutations, inflammation, etc.). Fragmented theories prevent comprehensive understanding. Unified theory enables rational intervention design targeting root causes. Physics-informed models (entropy, dissipation) provide quantitative framework for understanding aging as physical process.
causal_pathway_discovery: By integrating fragmented theories and diverse datasets, the platform identifies new causal pathways that connect different aspects of aging. This enables rational intervention design based on unified aging theory rather than correlation-based approaches.
comparison_with_baseline:
  target_discovery: "Traditional correlation-based approaches: identify associations, unclear causality. Gero platform: identifies causal pathways, enables rational intervention design, expands target space 10-20x."
  theory_synthesis: "Traditional manual synthesis: time-consuming, limited by human cognitive capacity, may miss connections. Gero platform: systematic integration using LLMs, identifies new causal pathways, accelerates research by 1-2 years."
  trajectory_mapping: "Traditional methods: analyze static snapshots, identify correlations. Gero platform: models dynamic trajectories, identifies causal relationships, separates irreversible aging from reversible diseases."
theory_synthesis_approach: "Fragmented theories of aging exist across multiple disciplines. Traditional manual synthesis is time-consuming and may miss connections. Gero's platform uses Large Language Models to systematically integrate diverse datasets and aging theories, identifying new causal pathways that would be difficult to discover through manual analysis."
```

## Lessons Learned

### Achievements

- Successfully developed LLM-based platform for synthesizing fragmented aging theories
- Trained models on 100M+ longitudinal medical records for trajectory mapping
- Published aging map in Nature Aging revealing cell-specific effects of longevity strategies
- Developed dissipative theory of aging framework published in npj Aging
- Identified new causal pathways through integrated theory synthesis in 2025
- Established research collaboration with Pfizer for fibrotic disease target discovery
- Created framework for separating irreversible aging from reversible diseases
- Enabled rational intervention design based on unified aging theory

### Challenges

- Fragmented theories of aging exist across multiple disciplines and are difficult to integrate manually
- Distinguishing causal relationships from correlations in aging research requires sophisticated analysis
- Separating irreversible aging processes from reversible diseases is theoretically and practically challenging
- Integration of diverse datasets requires careful handling of data quality and consistency

### Impact on Field

Gero's aging theory synthesis platform addresses a fundamental challenge in aging research: the fragmentation of theories across disciplines. By using LLMs to systematically integrate diverse datasets and aging theories, the platform identifies new causal pathways that enable rational intervention design. The publication of the aging map in Nature Aging and the dissipative theory framework demonstrate the scientific impact of this approach. The platform's ability to separate irreversible aging processes from reversible diseases provides a theoretical foundation for targeted interventions. The collaboration with Pfizer highlights the pharmaceutical industry's recognition of the value of this approach. The 2025 achievement of identifying new causal pathways through integrated theory synthesis shows the platform's potential to accelerate aging research by 1-2 years through unified theory enabling rational intervention design.

## Organizations

### Gero
**Legal Name**: Gero Pte. Ltd.
**Role in Project**: primary
**Role Description**: Primary organization - developer of the aging theory synthesis platform
**Organization Type**: company
**Status**: operational
**Founded**: 2015
**Website**: https://gero.ai
**Description**: Biotechnology company applying physics and machine learning to aging research
**Focus**: AI platforms for aging theory synthesis, trajectory mapping, and causal pathway discovery using large language models and physics-informed models

### Chugai Pharmaceutical
**Role in Project**: partner
**Role Description**: Joint research and license agreement partner for novel therapies
**Organization Type**: company
**Status**: operational
**Description**: Japanese pharmaceutical company specializing in prescription pharmaceuticals
**Focus**: Pharmaceutical development, antibody engineering

### Pfizer
**Role in Project**: partner
**Role Description**: Research collaboration partner for target discovery in fibrotic diseases
**Organization Type**: company
**Status**: operational
**Description**: Global pharmaceutical company
**Focus**: Pharmaceutical research and development

## Locations

### Gero Headquarters
**Type**: headquarters
**Address**: Singapore
**City**: Singapore
**Country**: Singapore
**Organizations**: Gero

## Products

### Aging Theory Synthesis Platform
**Alternative Names**: Trajectory Mapping Platform, Aging Trajectory Mapping System
**Type**: platform
**Status**: operational
**Role in Project**: primary
**Relationship Description**: Core AI platform for aging theory synthesis and trajectory mapping
**Description**: AI platform using Large Language Models (LLMs) to synthesize fragmented aging theories and integrate diverse datasets. The platform identifies new causal pathways from integrated data and expands theoretical understanding of aging. Trained on 100M+ longitudinal medical records to model aging trajectories and identify causal relationships underlying aging and disease.
**Mechanism of Action**: Uses Large Language Models (LLMs) for theory synthesis to integrate fragmented datasets and aging theories. Physics-informed models trained on 100M+ longitudinal medical records enable trajectory mapping and causal pathway discovery. The platform separates irreversible aging processes from reversible diseases using principles of thermodynamics and dynamic systems.
**Target**: Fragmented theories of aging, diverse aging datasets
**Pathway**: Causal pathways underlying aging and disease
**Capabilities**:
- Integrates fragmented aging theories using LLMs
- Identifies new causal pathways from integrated data
- Maps individual aging trajectories
- Separates irreversible aging from reversible diseases
- Expands theoretical understanding of aging
- Enables rational intervention design based on unified theory
**Indications**: [
  {
    "primary": "Aging theory integration",
    "secondary": "Causal pathway discovery, intervention target identification"
  }
]
**Technical Details**:
```yaml
results:
  2024:
  quantitative_metrics:
  impact: High - published in leading aging research journal
  publication: Nature Aging journal
  cell_specificity: Revealed cell-type-specific aging patterns requiring personalized interventions
  nature_aging_publication: Published aging map in Nature Aging revealing cell-specific effects of longevity strategies
  2025:
  causal_pathways: New causal pathways identified
  target_expansion: Expands search space for intervention targets
  theory_integration: LLMs for synthesis integrate fragmented theories
  quantitative_metrics:
  validation_status: "Causal pathways require experimental validation - path from theory to therapies: long-term"
  publication_impact: Published in Nature Aging (2024) and npj Aging (2025)
  research_acceleration: 1-2 years faster research through unified theory
  target_space_expansion: 10-20x expansion (from 10-20 directions to hundreds)
ai_methods:
  - Large Language Models (LLMs)
  - Theory Synthesis
  - Dataset Integration
  - Causal Pathway Discovery
  - Physics-Informed Models
validation:
  metrics: Theory integration quality, causal pathway identification accuracy, publication impact
  results: Published aging map in Nature Aging (2024), dissipative theory framework in npj Aging (2025), new causal pathways identified in 2025
  approach: Validation through publication in peer-reviewed journals (Nature Aging, npj Aging), comparison with existing theories, experimental validation of identified causal pathways
methodology:
  development_process: "Four-stage development: (1) Collection of 100M+ longitudinal medical records and aging research literature; (2) LLM training on scientific texts and medical data; (3) Integration with physics-informed models (entropy, dissipation); (4) Validation through peer-reviewed publications and causal pathway identification"
  validation_approach: Validation through publication in top-tier journals (Nature Aging, npj Aging), peer review, comparison with existing aging theories, experimental follow-up of identified causal pathways
  comparison_with_baseline: "Traditional manual synthesis: time-consuming, may miss connections, limited to human cognitive capacity. Gero platform: systematic integration using LLMs, identifies new causal pathways, accelerates research by 1-2 years"
training_data:
  size: 100M+ longitudinal medical records
  sources: Real-world patient data from medical databases, scientific publications on aging
  coverage: Multiple populations, diverse age ranges, various health conditions, comprehensive aging research corpus
  data_type: Longitudinal health records, aging research literature, biological datasets
model_architecture:
  type: Large Language Models (LLMs) for scientific text synthesis
  description: LLMs trained on scientific literature and medical data to synthesize fragmented aging theories. Physics-informed models incorporate thermodynamic principles (entropy, dissipation) to distinguish irreversible aging from reversible diseases.
  training_approach: "Multi-stage training: (1) Pre-training on scientific literature; (2) Fine-tuning on aging research papers and medical records; (3) Integration with physics-informed models"
training_parameters:
  note: Specific LLM architecture and training parameters not publicly disclosed. Models trained to synthesize theories and identify causal pathways from integrated datasets.
theoretical_framework:
  dissipative_aging:
  concept: Aging is a dissipative process in biological systems, similar to dynamic systems where dissipation occurs due to non-conservative forces.
  entropy_resilience:
  concept: Aging is associated with loss of systemic resilience due to increasing entropy. This concept allows separation of irreversible aging processes from reversible diseases.
  systemic_resistance:
  concept: The platform identifies targets for restoring systemic resistance and controlling the rate of aging and disease progression.
computational_requirements:
  note: Requires massive computational resources for training LLMs on 100M+ records and scientific literature. Inference for theory synthesis is computationally intensive.
```

## Key People

### Peter Fedichev
**Title**: Co-founder and CEO
**Participation Type**: founder
**Role in Project**: Co-founder, CEO
**Expertise**: Physics, computational biology, aging research, AI/ML applications in longevity, machine learning, graph neural networks; Physics, computational biology, aging research, AI/ML applications in longevity
**Biography**: Co-founder and CEO of Gero. Expert in physics, computational biology, aging research, and AI/ML applications in longevity. Leads Gero's AI/ML research team.

## Links

### [Gero AI - About](https://gero.ai/about)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: Company about page
**Description**: Company about page with information on research, publications, and team

### [Gero Enters Research Collaboration with Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/longevity-biotech-gero-entered-research-collaboration)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Relationship Description**: Pfizer partnership announcement
**Publication Date**: 2023-01-01
**Description**: Pfizer press release announcing research collaboration with Gero for target discovery in fibrotic diseases

### [Dissipative theory of aging based on dynamic systems analysis](https://www.nature.com/articles/s41514-025-00277-2)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Relationship Description**: npj Aging publication
**Publication Date**: 2025-01-01
**Description**: Dissipative theory of aging based on analysis of dynamic systems and use of cell aging maps
**Metadata**:
```yaml
journal: npj Aging
```

### [Aging map revealing cell-specific effects of longevity strategies](https://www.nature.com/articles/s43587-024-00631-1)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Relationship Description**: Nature Aging publication
**Publication Date**: 2024-01-01
**Description**: Published aging map in Nature Aging revealing cell-specific effects of longevity strategies
**Metadata**:
```yaml
journal: Nature Aging
```

### [Peter Fedichev - Wikipedia](https://en.wikipedia.org/wiki/Peter_Fedichev)
**Type**: reference
**Relevance**: primary
**Category**: reference
**Relationship Description**: Founder information
**Description**: Wikipedia article about Gero founder and CEO Peter Fedichev

### [Gero AI - Hacking Aging](https://www.gero.ai/hacking-aging)
**Type**: website
**Relevance**: primary
**Category**: source
**Relationship Description**: Company approach to aging research
**Description**: Company website describing Gero's approach to aging research, trajectory mapping, physics-informed models, and theory synthesis

### [Gero and Chugai Enter into Joint Research and License Agreement](https://www.gero.ai/news/chugai-and-gero-enter-into-joint-research-and-license-agreement-to-develop-novel-therapies-for-age-related-diseases)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Relationship Description**: Chugai partnership announcement
**Publisher**: Gero
**Publication Date**: 2025-07-07
**Description**: Announcement of joint research and license agreement with Chugai Pharmaceutical to develop novel therapies for age-related diseases

## Events

### Pfizer Partnership
**Date**: 2023-01-01
**Type**: partnership
**Description**: Announced research collaboration with Pfizer for target discovery in fibrotic diseases
**Details**:
```yaml
focus: Fibrotic disease target discovery
partner: Pfizer
```

### Nature Aging Publication
**Date**: 2024-01-01
**Type**: publication
**Description**: Published aging map in Nature Aging revealing cell-specific effects of longevity strategies
**Details**:
```yaml
publication: Nature Aging
```

### Causal Pathways Identified
**Date**: 2025-01-01
**Type**: milestone
**Description**: New causal pathways identified through LLM-based theory synthesis. Expanded search space for intervention targets.
**Details**:
```yaml
achievement: Causal pathway discovery through integrated theory synthesis
```

## Partnerships

### strategic
**Date**: 2025-07-01
**Focus**: Development of novel therapies for age-related diseases
**Description**: Joint research and license agreement to develop novel therapies for age-related diseases. Combines Gero's AI-driven target discovery and trajectory mapping with Chugai's antibody engineering technologies.
**Partner Organizations**:
- Chugai Pharmaceutical (partner)
**Details**:
```yaml
status: Active
```

### research
**Date**: 2023-01-01
**Focus**: Target discovery for fibrotic diseases
**Description**: Research collaboration to apply Gero's machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
**Partner Organizations**:
- Pfizer (partner)
**Details**:
```yaml
status: Ongoing
```
